Twist Bioscience Corporation (NASDAQ:TWST) Receives $84.30 Consensus Target Price from Analysts

Shares of Twist Bioscience Corporation (NASDAQ:TWST) have received a consensus recommendation of “Moderate Buy” from the ten brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $90.30.

TWST has been the topic of several analyst reports. Leerink Partners set a $110.00 target price on shares of Twist Bioscience in a report on Thursday. Canaccord Genuity Group lifted their price target on shares of Twist Bioscience from $90.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, July 14th. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research report on Wednesday, June 24th. Guggenheim upped their price objective on shares of Twist Bioscience from $60.00 to $107.00 and gave the stock a “buy” rating in a research note on Monday, June 29th. Finally, TD Cowen upped their price objective on shares of Twist Bioscience from $68.00 to $89.00 and gave the stock a “buy” rating in a research note on Monday, June 15th.

Twist Bioscience Price Performance

Shares of TWST stock opened at $93.85 on Friday. The stock’s fifty day simple moving average is $77.74 and its 200 day simple moving average is $58.01. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.70 and a quick ratio of 2.42. The firm has a market cap of $5.84 billion, a price-to-earnings ratio of -70.56 and a beta of 2.11. Twist Bioscience has a one year low of $23.30 and a one year high of $105.47.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.22). The company had revenue of $110.72 million for the quarter, compared to analyst estimates of $107.64 million. Twist Bioscience had a negative return on equity of 26.73% and a negative net margin of 19.85%.The business’s revenue was up 19.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.66) earnings per share. On average, analysts expect that Twist Bioscience will post -2.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Twist Bioscience news, CEO Emily M. Leproust sold 18,880 shares of Twist Bioscience stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $95.00, for a total value of $1,793,600.00. Following the completion of the transaction, the chief executive officer owned 824,039 shares in the company, valued at approximately $78,283,705. The trade was a 2.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Dennis Cho sold 14,205 shares of the business’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $89.75, for a total value of $1,274,898.75. Following the completion of the transaction, the insider directly owned 105,141 shares in the company, valued at approximately $9,436,404.75. This represents a 11.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 60,382 shares of company stock worth $4,861,215 over the last ninety days. 3.08% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in TWST. Quarry LP acquired a new stake in Twist Bioscience in the 3rd quarter valued at about $28,000. Western Wealth Management LLC bought a new position in shares of Twist Bioscience in the first quarter worth about $31,000. Strs Ohio acquired a new position in shares of Twist Bioscience during the first quarter worth approximately $33,000. Strategic Advocates LLC lifted its position in shares of Twist Bioscience by 562.7% during the fourth quarter. Strategic Advocates LLC now owns 1,067 shares of the company’s stock worth $34,000 after purchasing an additional 906 shares in the last quarter. Finally, SBI Securities Co. Ltd. grew its stake in shares of Twist Bioscience by 68.9% during the fourth quarter. SBI Securities Co. Ltd. now owns 1,400 shares of the company’s stock valued at $44,000 after purchasing an additional 571 shares during the last quarter.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.